2023
Diagnosis and management of mineral and bone disorders in infants with CKD: clinical practice points from the ESPN CKD-MBD and Dialysis working groups and the Pediatric Renal Nutrition Taskforce.
Bacchetta J, Schmitt CP, Bakkaloglu SA, Cleghorn S, Leifheit-Nestler M, Prytula A, Ranchin B, Schön A, Stabouli S, Van de Walle J, Vidal E, Haffner D, Shroff R. Pediatr Nephrol. 2023; Feb 14 online ahead of print.
hier
2022
High phosphate-induced progressive proximal tubular injury is associated with the activation of Stat3/Kim-1 signaling pathway and macrophage recruitment.
Richter B, Kapanadze T, Weingärtner N, Walter S, Vogt I, Grund A, Schmitz J, Bräsen JH, Limbourg FP, Haffner D, Leifheit-Nestler M. FASEB J. 2022; 36:e22407.
hier
Pathophysiologische Grundlagen der X-chromosomalen Hyperphosphatämie.
Leifheit-Nestler M. In X-chromosomale Hypophosphatämie – Phosphatdiabetes – XLH. UNI-MED Science, 2022. ISBN 978-3-8374-2442-3.
hier
Rickets guidance: part II – management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Pediatr Nephrol. 2022; 37:2289-2302.
hier
Phosphate is a Cardiovascular Toxin.
Leifheit-Nestler M, Vogt I, Haffner D, Richter B. In Phosphate Metabolism. Adv Exp Med Biol. 2022; 1362:107-134.
hier
Editorial: Mineral and Bone Disorder in CKD.
Printza N, Dotis J, Sinha MD, Leifheit-Nestler M. Front Pediatr. 2022; 10:856656.
hier
Comprehensive expression analysis of cardiac fibroblast growth factor 23 in health and pressure-induced cardiac hypertrophy.
Eitner F, Richter B, Schwänen S, Szaroszyk M, Vogt I, Grund A, Thum T, Heineke J, Haffner D, Leifheit-Nestler M. Front Cell Dev Biol. 2022; 9:791479.
hier
Muscle and bone impairment in infantile nephropathic cystinosis: new concepts.
Haffner D, Leifheit-Nestler M, Alioli C, Bacchetta J. Cells. 2022; 11:170.
hier
Rickets guidance: part I – diagnostic workup.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Pediatr Nephrol. 2022; 37:2013-2036.
hier
2021
FGF23 and heart and vascular disease.
Leifheit-Nestler M, Richter B, Haffner D. in Fibroblast Growth Factor 23. Elsevier 2021, 133-156; ISBN 9780128180365.
hier
Cardiac FGF23 excess does not induce left ventricular hypertrophy in healthy mice.
Leifheit-Nestler M, Wagner MA, Richter B, Eitner F, Böckmann I, Vogt I, Grund A, Hille SS, Foinquinos A, Zimmer K, Thum T, Müller OJ, Haffner D. Front Cell Dev Biol. 2021; 9:745892.
hier
How FGF23 shapes multiple organs in chronic kidney disease.
Leifheit-Nestler M and Haffner D. Mol Cell Pediatr. 2021; 8:12.
hier
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease – A pediatric perspective.
Grund A, Sinha MD, Haffner D, Leifheit-Nestler M. Front Pediatr. 2021; 9:702719.
hier
Renal effects of growth hormone in health and kidney disease.
Haffner D, Grund A, Leifheit-Nestler M. Pediatr Nephrol 2021; 36:2511-2530.
hier
Bone evaluation in paediatric chronic kidney disease: Clinical practice points from the European Society for Paediatric Nephrology chronic kidney disease-Mineral and bone disorder and dialysis working groups and the European Renal Osteodystrophy working group, an initiative of the CKD-MBD working group of the ERA-EDTA.
Sevcan A. Bakkaloglu SA*, Bacchetta J *, Lalayiannis AD, Leifheit-Nestler M, Stabouli S, Haarhaus ML, ReuszG, Groothoff J, Schmitt CP, Evenepoel P, Shroff R*, Haffner D*, on behalf of the European Society for Paediatric Nephrology (ESPN) Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) and Dialysis working groups and the European Renal Osteodystrophy (EUROD) workgroup, an Initiative of the CKD-MBD working group of the European Renal Association–European Dialysis and Transplantat Association (ERA-EDTA). Nephrol Dial Transplant. 2021; 36:413-425.
hier
Active vitamin D is cardioprotective in experimental uraemia but not in children with CKD stages 3-5.
Schön A*, Leifheit-Nestler M*, Deppe J, Fischer DC, Bayazit AK, Obrycki L, Canpolat N, Bulut IK, Azukaitis K, Yilmaz A, Mir S, Yalcinkaya F, Soylemezoglu O, Melk A, Stangl GI, Behnisch R, Shroff R, Bacchetta J, Querfeld U, Schaefer F, Haffner D; for the 4C Study consortium and the ESPN CKD-MBD working group. Nephrol Dial Transplant. 2021; 36:442-451.
hier
CKD-MBD post kidney transplantation.
Haffner D and Leifheit-Nestler M. Pediatr Nephrol. 2021; 36:41-50.
hier
2020
Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities.
Ewert A, Leifheit-Nestler M, Hohenfellner K, Büscher A, Kemper MJ, Oh J, Billing H, Thumfart J, Stangl G, Bauer AC, Föller M, Feger M, Weber LT, Acham-Roschnitz B, Arbeiter K, Tönshoff B, Zivicnjak M, Haffner D. J Clin Endocriol Metab 2020; 105:e2738-e2752.
hier
Treatment of hyperphosphatemia: The dangers of aiming for normal PTH levels.
Haffner D and Leifheit-Nestler M. Pediatr Nephrol. 2020; 35:485-491.
hier
The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid.
Kranaster L, Hoyer C, Mindt S, Neumeier M, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Sartorius A. Eur Arch Psychiatry Clin Neurosci. 2020; 270:911-919.
hier
2019
FGF23 and phosphate – Cardiovascular toxins in CKD.
Vogt I, Haffner D and Leifheit-Nestler M. Toxins (Basel). 2019; 11:647.
hier
FGF23-mediated activation of RAAS promotes cardiac hypertrophy and fibrosis.
Böckmann I, Lischka J, Richter B, Deppe J, Rahn A, Fischer DC, Heineke J, Haffner D, Leifheit-Nestler M. Int J Mol Sci. 2019; 20:4634.
hier
Peripheral levels of anti-aging hormone Klotho in patients with depression.
Sartorius A, Gilles M, Pfeifer AM, Deuschle M, Hoyer C, Haffner D, Leifheit-Nestler M, Kranaster L. J Neural Transm (Vienna). 2019; 126:771-776.
hier
Biomarker of Antidepressant Efficacy of Electroconvulsive Theraphy: An Exploratory Cerebrospinal Fluid Study.
Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Janke C, Thiel M, Sartorius A. Neuropsychobiology. 2019; 77:13-22.
hier
2018
Impact of altered mineral metabolism on pathological cardiac remodeling in elevated fibroblast growth factor 23.
Leifheit-Nestler M, Richter B, Basaran M, Nespor J, Vogt I, Alesutan I, Voelkl J, Lang F, Heineke J, Kricks, Haffner D. Front Endocrinol (Lausanne). 2018; 9:333.
hier
Paracrine effects of FGF23 on the heart.
Leifheit-Nestler M and Haffner D. Front Endocrinol (Lausanne). 2018; 9:278.
hier
Impaired microcirculation in children after kidney transplantation: Everolimus versus myophenolate based immunosuppression regimen.
Ruben S, Kreuzer M, Büscher A, Büscher R, Thumfart J, Querfeld U, Staude H, Ahlenstiel-Grunow T, Melk A, Fischer DC, Leifheit-Nestler M, Pape L, Haffner D. Kidney Blood Press Res. 2018; 43:793-806.
hier
Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with CKD.
Lerch C, Shroff R, Wan M, Rees L, Aitkenhead H, Bulut IP, Thurn D, Bayazit AK Nimierska A, Canpolat N, Duzova A, Azukaitis K, Yimaz E, Yalcinkaya F, Harambat J, Kiyak A, Alpay H, Anarat A, Habbig S, Wygoda S, Zaloszyk A, Soylemezoglu O, Caliskan S, Baskin E, Candan C, Rosales A, Melk A, Querfeld U, Leifheit-Nestler M, Sander A, Schaefer F, Haffner D; for the 4C Study consortium and the ESPN CKD-MBD working group. Nephrol Dial Transplant. 2018; 33:2208-2217.
hier
Fibroblast growth factor 23 is induced by activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts.
Leifheit-Nestler M, Kirchhoff F, Nespor J, Richter B, Soetje B, Klintschar M, Heineke J, Haffner D. Nephrol Dial Transplant. 2018; 33:1722-1734.
hier
Electroconvulsive therapy enhances the anti-ageing hormone Klotho in the cerebrospinal fluid of patients with major depression.
Hoyer C, Sartorius A, Aksay SS, Bumb JM, Janke C, Thiel M, Haffner D, Leifheit-Nestler M*, Kranaster L*. Eur Neuropsychopharmacol. 2018; 28:428-435.
*These authors contributed equally to this work
hier
2017
Comparision of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mous, a murine homolog of X-linked hyperphosphatemia.
Leifheit-Nestler M, Kucka J, Yoshizawa E, Behets G, D´Haese P, Bergen C, Meier M, Fischer DC, Haffner D. Bone. 2017; 103:224-232.
hier
Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
Leifheit-Nestler M, Grabner A, Hermann L, Richter B, Schmitz K, Fischer DC, Yanucil C, Faul C, Haffner D. Nephrol Dial Transplant. 2017; 32:1493-1503.
hier
Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome.
Kreuzer M, Sollmann L, Ruben S, Leifheit-Nestler M, Fischer DC, Pape L, Haffner D. Pediatr Nephrol. 2017; 32:1005-1011.
hier
Extrarenal effects of FGF23.
Haffner D and Leifheit-Nestler M. Pediatr Nephrol. 2017; 32:753-765.
hier
Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells.
Richter B, Haller J, Haffner D, Leifheit-Nestler M. Pfluger Arch. 2016; 468:1621-1635.
hier
Klotho and Fibroblast Growth Factor 23 in Cerebrospinal Fluid in Children.
Kunert SK, Hartmann H, Haffner D, Leifheit-Nestler M. J Bone Mineral Metab. 2017; 35:215-226.
hier
2016
Fibroblast growth factor 23 signaling in hippocampal cells: Impact on neuronal morphology and synaptic density.
Hensel N, Schön A, Konen T, Lübben V, Förthmann B, Baron O, Grothe C, Leifheit-Nestler M*, Claus P*, Haffner D*. J Neurochem. 2016; 137:756-769.
*These authors contributed equally to this work
hier
Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Leifheit-Nestler M, große Siemer R, Flasbart K, Richter B, Kirchhoff K, Ziegler WH, Klintschar M, Becker JU, ErbersdoblerA, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D. Nephrol Dial Transplant. 2016; 31:1088-1099.
hier
2015
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C. Cell Metab. 2015; 22:1020-1032.
hier